A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)

Lung Cancer

Volumn 84, Issue 1, 2014, Pages 67-72

  Murakami, Haruyasu ^a   Yamamoto, Nobuyuki ^a,b   Shibata, Taro ^c   Takeda, Koji ^d   Ichinose, Yukito ^e   Ohe, Yuichiro ^f   Yamamoto, Noboru ^g   Takeda, Yuichiro ^h   Kudoh, Shinzoh ⁱ   Atagi, Shinji ^j   Satouchi, Miyako ^k   Kiura, Katsuyuki ^l   Nogami, Naoyuki ^m   Endo, Masahiro ^a   Watanabe, Hirokazu ^g   Tamura, Tomohide ^g  

^a SHIZUOKA CANCER CENTER   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

ⁱ OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^k HYOGO CANCER CENTER   (Japan)

^l OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^m NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

more..

Author keywords

Amrubicin; Chemotherapy; Etoposide; Phase II; Refractory; Small cell lung cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; AMRUBICIN; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; TOPOTECAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPONATREMIA; INFECTION; JAPAN; LEUKOCYTE COUNT; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PATIENT HISTORY OF RADIOTHERAPY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY LUNG SMALL CELL CANCER; SENSORY NEUROPATHY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AMRUBICIN; CHEMOTHERAPY; ETOPOSIDE; PHASE II; REFRACTORY; SMALL-CELL LUNG CANCER;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETREATMENT; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84895435001     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.01.012     Document Type: Article

References (22)

1. Jackman D.M., Johnson B.E. Small-cell lung cancer. Lancet 2005, 366:1385-1396.
2. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
3. Hanna N., Bunn P.A., Langer C., Einhorn L., Guthrie T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038-2043.
4. Lara P.N., Natale R., Crowley J., Lenz H.J., Redman M.W., Carleton J.E., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009, 27:2530-2535.
5. Turrisi A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265-271.
6. Takada M., Fukuoka M., Kawahara M., Sugiura T., Yokoyama A., Yokota S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002, 20:3054-3060.
7. Giaccone G., Donadio M., Bonardi G., Testore F., Calciati A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988, 6:1264-1270.
8. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997, 15:2090-2096.
9. Inoue A., Sugawara S., Yamazaki K., Maemondo M., Suzuki T., Gomi K., et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008, 26:5401-5406.
10. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
11. Perez-Soler R., Glisson B.S., Lee J.S., Fossella F.V., Murphy W.K., Shin D.M., et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996, 14:2785-2790.
12. Noda T., Watanabe T., Kohda A., Hosokawa S., Suzuki T. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 1998, 16:121-128.
13. Onoda S., Masuda N., Seto T., Eguchi K., Takiguchi Y., Isobe H., et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006, 24:5448-5453.
14. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
15. Jotte R., Von Pawel J., Spigel D.R., Socinski M.A., O'Brien M., Paschold E.H., et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). ASCO Meeting Abstracts 2011, 29:7000.
16. Ettinger D.S., Jotte R., Lorigan P., Gupta V., Garbo L., Alemany C., et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010, 28:2598-2603.
17. Gupta R.S., Gupta R., Eng B., Lock R.B., Ross W.E., Hertzberg R.P., et al. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 1988, 48:6404-6410.
18. Sugimoto Y., Tsukahara S., Oh-hara T., Isoe T., Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990, 50:6925-6930.
19. Sugimoto Y., Tsukahara S., Oh-hara T., Liu L.F., Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 1990, 50:7962-7965.
20. Tan K.B., Mattern M.R., Eng W.K., McCabe F.L., Johnson R.K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989, 81:1732-1735.
21. Kotani Y., Satouchi M., Ando M., Nakagawa K., Yamamoto N., Ichinose Y., et al. A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509. ASCO Meeting Abstracts 2012, 30:7003.
22. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.